Syntis Bio

Syntis Bio is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestines unique biology to provide accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the worlds most prevalent conditions. Syntis is rapidly advancing a pipeline of oral therapies engineered for optimization in the small intestine, the bodys nexus for metabolic control, digestion and drug absorption. The companys lead program, SYNT-101, is a once-daily oral pill for the treatment of obesity that mimics the effects of gastric bypass surgery. SYNT-101 leverages the power of SYNTTM (SYNthetic Tissue-lining), an oral technology developed by Syntis founders that delivers a safe, transient polymer coating to the duodenum that controls nutrient uptake, as well as enhances both gut-restricted enzyme efficacy and systemic drug absorption for up to 24 hours. Syntis is headquartered in Boston